Nucleoside phosphoramidates
Disclosed herein are nucleoside phosphoramidates and their use as agents for treating viral diseases. These compounds are inhibitors of RNA-dependent RNA viral replication and are useful as inhibitors of HCV NS5B polymerase, as inhibitors of HCV replication and for treatment of hepatitis C infection in mammals.
1. A compound represented by the following structure:
2. A compound represented by the following structure:
3. The compound according to claim 1 , wherein the compound is crystalline.
4. A process for preparing the compound according to claim 3 , which comprises:
crystallizing a compound represented by the following structure:
from a second composition comprising
a) a first composition;
b) pentafluorophenol;
c) a non-nucleophilic base; and
d) a liquid composition;
wherein the first composition comprises the compound represented by the following structure:
and the compound represented by the following structure:
5. A process for preparing a compound represented by the following structure (S P -4):
which comprises:
crystallizing a compound represented by the following structure:
from a second composition comprising
a) a first composition;
b) pentafluorophenol;
c) a non-nucleophilic base; and
d) a liquid composition;
wherein the first composition comprises the compound represented by the following structure:
and the compound represented by the following structure:
6. A process for preparing a compound represented by the following structure (S P -4):
which comprises:
contacting the compound of claim 1 with a product obtained by reacting a compound represented by the following structure:
with a t-butylmagnesium halide.